Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Brief summary: Allogeneic γδT cells from healthy donor will be administrated intravenously to patients with the MDR-TB，and then the safety and efficacy of γδT cells will be evaluated.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhinan Yin, Ph.D.
• Collaborator: Shenzhen Third People's Hospital
• Treatments: Antitubercular Agents

Criteria

Inclusion Criteria:

1. Aged 18-50 years old, male or female;

2. Informed consent;

3. Patients with multidrug-resistant tuberculosis diagnosed by positive sputum smear and tubercle bacillus culture.

Exclusion Criteria:

1. AIDS, hepatitis B and other viruses, bacterial infections;

2. Patients with other diseases such as diabetes, cancer, hypertension, coronary heart disease, endocrine system diseases, mental diseases, neurological diseases, and vascular circulatory diseases;

3. Others After being evaluated by clinicians participating in this project, it is not suitable to participate in immune cell therapy;

4. Those who do not agree to be included.